publication . Article . Other literature type . 2012

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience

Baum, Richard P.; Kulkarni, Harshad R.;
Open Access
  • Published: 01 Jan 2012 Journal: Theranostics, volume 2, pages 437-447 (issn: 1838-7640, Copyright policy)
  • Publisher: Ivyspring International Publisher
Abstract
<p>The acronym THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the pillars of medicine and takes into account personalized management of disease for a specific patient<i>.</i> Molecular phenotypes of neoplasms can be determined by molecular imaging with specific probes using positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or optical methods, so that the treatment is specifically targeted against the tumor and its environment. To meet these demands, we need to define the targets, ligands, coupling and labeling chemistry, the most appropriate radionuclides, biodistributi...
Subjects
free text keywords: Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Molecular imaging, Positron emission tomography, medicine.diagnostic_test, medicine, Radiology, medicine.medical_specialty, Neuroendocrine tumors, medicine.disease, Radionuclide therapy, business.industry, business, PET-CT, Magnetic resonance imaging, Nuclear medicine, Single-photon emission computed tomography, Biodistribution, R, Review, THERANOSTICS, personalized radionuclide therapy.
37 references, page 1 of 3

Rösch, F, Baum, RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011; 40: 6104-11 [PubMed]

Zhernosekov, KP, Filosofov, DV, Baum, RP. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48: 1741-8 [PubMed]

Lamberts, SWJ, Reubi, JC, Krenning, EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol. 1994; 21: 1-5 [PubMed]

Krenning, EP, Kwekkeboom, DJ, de Jong, M. Essentials of peptide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol. 1994; 21: 6-14 [PubMed]

Hofmann, M, Maecke, H, Borner, R. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging. 2001; 28: 1751-7

Buchmann, I, Henze, M, Engelbrecht, S. Comparison of 68Ga-DOTATOC PET and 111In-DTPA-OC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007; 34: 1617-26 [PubMed]

Gabriel, M, Decristoforo, C, Kendler, D. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48: 508-18 [PubMed]

Ambrosini, V, Campana, D, Bodei, L. 68Ga- DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51: 669-73 [OpenAIRE] [PubMed]

Srirajaskanthan, R, Kayani, I, Quigley, AM. The role of 68Ga- DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In- DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51: 875-82 [OpenAIRE] [PubMed]

Boy, C, Heusner, TA, Poeppel, TD. (68)Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging. 2011; 38: 1224-36 [PubMed]

Kaemmerer, D, Peter, L, Lupp, A. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38: 1659-68 [PubMed]

Kowalski, J, Henze, M, Schuhmacher, J. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5: 42-8 [PubMed]

Baum, RP, Prasad, V, Wahl, R. PET and PET/CT Imaging of Neuroendocrine Tumors. Principles and Practice of PET and PET/CT, 2nd ed. 2008: 411-37

Baum, RP, Prasad, V, Hommann, M. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results in Cancer Research. 2007; 170: 225-42 [PubMed]

Prasad, V, Ambrosini, V, Hommann, M. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010; 37: 67-77 [PubMed]

37 references, page 1 of 3
Abstract
<p>The acronym THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the pillars of medicine and takes into account personalized management of disease for a specific patient<i>.</i> Molecular phenotypes of neoplasms can be determined by molecular imaging with specific probes using positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or optical methods, so that the treatment is specifically targeted against the tumor and its environment. To meet these demands, we need to define the targets, ligands, coupling and labeling chemistry, the most appropriate radionuclides, biodistributi...
Subjects
free text keywords: Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Molecular imaging, Positron emission tomography, medicine.diagnostic_test, medicine, Radiology, medicine.medical_specialty, Neuroendocrine tumors, medicine.disease, Radionuclide therapy, business.industry, business, PET-CT, Magnetic resonance imaging, Nuclear medicine, Single-photon emission computed tomography, Biodistribution, R, Review, THERANOSTICS, personalized radionuclide therapy.
37 references, page 1 of 3

Rösch, F, Baum, RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011; 40: 6104-11 [PubMed]

Zhernosekov, KP, Filosofov, DV, Baum, RP. Processing of generator-produced 68Ga for medical application. J Nucl Med. 2007; 48: 1741-8 [PubMed]

Lamberts, SWJ, Reubi, JC, Krenning, EP. Somatostatin and the concept of peptide receptor scintigraphy in oncology. Semin Oncol. 1994; 21: 1-5 [PubMed]

Krenning, EP, Kwekkeboom, DJ, de Jong, M. Essentials of peptide receptor scintigraphy with emphasis on somatostatin analog octreotide. Semin Oncol. 1994; 21: 6-14 [PubMed]

Hofmann, M, Maecke, H, Borner, R. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med Mol Imaging. 2001; 28: 1751-7

Buchmann, I, Henze, M, Engelbrecht, S. Comparison of 68Ga-DOTATOC PET and 111In-DTPA-OC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007; 34: 1617-26 [PubMed]

Gabriel, M, Decristoforo, C, Kendler, D. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007; 48: 508-18 [PubMed]

Ambrosini, V, Campana, D, Bodei, L. 68Ga- DOTA-NOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010; 51: 669-73 [OpenAIRE] [PubMed]

Srirajaskanthan, R, Kayani, I, Quigley, AM. The role of 68Ga- DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In- DTPA-octreotide scintigraphy. J Nucl Med. 2010; 51: 875-82 [OpenAIRE] [PubMed]

Boy, C, Heusner, TA, Poeppel, TD. (68)Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging. 2011; 38: 1224-36 [PubMed]

Kaemmerer, D, Peter, L, Lupp, A. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011; 38: 1659-68 [PubMed]

Kowalski, J, Henze, M, Schuhmacher, J. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5: 42-8 [PubMed]

Baum, RP, Prasad, V, Wahl, R. PET and PET/CT Imaging of Neuroendocrine Tumors. Principles and Practice of PET and PET/CT, 2nd ed. 2008: 411-37

Baum, RP, Prasad, V, Hommann, M. Receptor PET/CT imaging of neuroendocrine tumors. Recent Results in Cancer Research. 2007; 170: 225-42 [PubMed]

Prasad, V, Ambrosini, V, Hommann, M. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010; 37: 67-77 [PubMed]

37 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue